Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Selective biocatalytic hydroxylation of unactivated methylene C-H bonds in cyclic alkyl substrates.

Sarkar MR, Dasgupta S, Pyke SM, Bell SG.

Chem Commun (Camb). 2019 Apr 23;55(34):5029-5032. doi: 10.1039/c9cc02060h.

PMID:
30968888
2.

Facilitating adaptive management in a government program: A household energy efficiency case study.

Curtis J, Graham A, Ghafoori E, Pyke S, Kaufman S, Boulet M.

J Environ Manage. 2017 Feb 1;187:89-95. doi: 10.1016/j.jenvman.2016.11.033. Epub 2016 Nov 22.

PMID:
27886585
3.

Best practice for statisticians in industry sponsored trials.

Julious SA, Pyke S, Hughes S.

BMJ. 2011 Mar 15;342:d1636. doi: 10.1136/bmj.d1636. No abstract available.

PMID:
21406524
4.

In vivo activity of benzoyl ester clerodane diterpenoid derivatives from Dodonaea polyandra.

Simpson BS, Claudie DJ, Gerber JP, Pyke SM, Wang J, McKinnon RA, Semple SJ.

J Nat Prod. 2011 Apr 25;74(4):650-7. doi: 10.1021/np100701s. Epub 2011 Mar 7.

PMID:
21381684
5.

The potential for bias in reporting of industry-sponsored clinical trials.

Pyke S, Julious SA, Day S, O'Kelly M, Todd S, Matcham J, Seldrup J.

Pharm Stat. 2011 Jan-Feb;10(1):74-9. doi: 10.1002/pst.429.

PMID:
21275037
6.

Making available information from studies sponsored by the pharmaceutical industry: some current practices.

O'Kelly M, Julious SA, Pyke S, Day S, Todd S, Seldrup J, Matcham J.

Pharm Stat. 2011 Jan-Feb;10(1):60-9. doi: 10.1002/pst.430.

PMID:
21275036
7.

Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.

Matcham J, Julious S, Pyke S, O'Kelly M, Todd S, Seldrup J, Day S.

Pharm Stat. 2011 Jan-Feb;10(1):70-3. doi: 10.1002/pst.417.

PMID:
20187020
8.

Sequential and selective Buchwald-Hartwig amination reactions for the controlled functionalization of 6-bromo-2-chloroquinoline: synthesis of ligands for the Tec Src homology 3 domain.

Smith JA, Jones RK, Booker GW, Pyke SM.

J Org Chem. 2008 Nov 21;73(22):8880-92. doi: 10.1021/jo801808r. Epub 2008 Oct 25.

PMID:
18950225
9.

Characterisation and in vitro cytotoxicity of triorganophosphinegold(i) 2-mercaptobenzoate complexes.

de Vos D, Clements P, Pyke SM, Smyth DR, Tiekink ER.

Met Based Drugs. 1999;6(1):31-40. doi: 10.1155/MBD.1999.31.

10.

Carbonyl-scavenging drugs & protection against carbonyl stress-associated cell injury.

Burcham PC, Kaminskas LM, Tan D, Pyke SM.

Mini Rev Med Chem. 2008 Apr;8(4):319-30. Review.

PMID:
18473924
11.

Antimicrobial compounds from the Australian desert plant Eremophila neglecta.

Ndi CP, Semple SJ, Griesser HJ, Pyke SM, Barton MD.

J Nat Prod. 2007 Sep;70(9):1439-43. Epub 2007 Sep 11.

PMID:
17844993
12.

Antimicrobial compounds from Eremophila serrulata.

Ndi CP, Semple SJ, Griesser HJ, Pyke SM, Barton MD.

Phytochemistry. 2007 Nov;68(21):2684-90. Epub 2007 Jul 12.

PMID:
17631925
13.

Michael addition of acrolein to lysinyl and N-terminal residues of a model peptide: targets for cytoprotective hydrazino drugs.

Kaminskas LM, Pyke SM, Burcham PC.

Rapid Commun Mass Spectrom. 2007;21(7):1155-64.

PMID:
17318925
14.

Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography.

Davies BJ, Herbert MK, Culbert JA, Pyke SM, Coller JK, Somogyi AA, Milne RW, Sallustio BC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 17;832(1):114-20. Epub 2006 Jan 24.

PMID:
16434242
16.
17.

Synthesis of N-benzylated-2-aminoquinolines as ligands for the Tec SH3 domain.

Inglis SR, Jones RK, Booker GW, Pyke SM.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):387-90. Epub 2005 Nov 2.

PMID:
16260132
18.

Synthesis of 5-, 6- and 7-substituted-2-aminoquinolines as SH3 domain ligands.

Inglis S, Jones R, Fritz D, Stojkoski C, Booker G, Pyke S.

Org Biomol Chem. 2005 Jul 21;3(14):2543-57. Epub 2005 Jun 13.

PMID:
15999186
19.

Identification and specificity studies of small-molecule ligands for SH3 protein domains.

Inglis SR, Stojkoski C, Branson KM, Cawthray JF, Fritz D, Wiadrowski E, Pyke SM, Booker GW.

J Med Chem. 2004 Oct 21;47(22):5405-17.

PMID:
15481978
20.

Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde.

Kaminskas LM, Pyke SM, Burcham PC.

Org Biomol Chem. 2004 Sep 21;2(18):2578-84. Epub 2004 Aug 20.

PMID:
15351821
21.

Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice.

Kaminskas LM, Pyke SM, Burcham PC.

J Pharmacol Exp Ther. 2004 Sep;310(3):1003-10. Epub 2004 May 6.

PMID:
15131244
22.

Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity.

Burcham PC, Fontaine FR, Kaminskas LM, Petersen DR, Pyke SM.

Mol Pharmacol. 2004 Mar;65(3):655-64.

PMID:
14978244
23.

Reactivity with Tris(hydroxymethyl)aminomethane confounds immunodetection of acrolein-adducted proteins.

Burcham PC, Fontaine FR, Petersen DR, Pyke SM.

Chem Res Toxicol. 2003 Oct;16(10):1196-201.

PMID:
14565760
24.

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.

Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN.

J Allergy Clin Immunol. 2003 Jul;112(1):29-36.

PMID:
12847476
25.

Sudden, unexpected cardiac or unexplained death in England: a national survey.

Bowker TJ, Wood DA, Davies MJ, Sheppard MN, Cary NR, Burton JD, Chambers DR, Dawling S, Hobson HL, Pyke SD, Riemersma RA, Thompson SG.

QJM. 2003 Apr;96(4):269-79.

PMID:
12651971
26.

Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products.

Burcham PC, Kaminskas LM, Fontaine FR, Petersen DR, Pyke SM.

Toxicology. 2002 Dec 27;181-182:229-36. Review.

PMID:
12505316
27.

MIASMA: asthma exacerbation reduction with salmeterol.

Shrewsbury S, Pyke S.

Chest. 2002 Mar;121(3):1002-4. No abstract available.

PMID:
11888994
28.
29.

In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus.

Semple SJ, Pyke SM, Reynolds GD, Flower RL.

Antiviral Res. 2001 Mar;49(3):169-78.

PMID:
11428243
30.

Clinical effectiveness on an acute in-patient psychiatric unit.

Collier EH, Pyke S.

Clin Perform Qual Health Care. 2000;8(3):158-63.

PMID:
11185831
31.

Designing bronchial biopsy studies.

Poulter LW, Burke CM, Jarjour NN, Pyke SD.

Respir Med. 2000 Oct;94 Suppl F:S3-8.

32.
33.

Antiviral flavonoid from Pterocaulon sphacelatum, an Australian Aboriginal medicine.

Semple SJ, Nobbs SF, Pyke SM, Reynolds GD, Flower RL.

J Ethnopharmacol. 1999 Dec 15;68(1-3):283-8.

PMID:
10624889
34.
35.

The design and analysis of paired cluster randomized trials: an application of meta-analysis techniques.

Thompson SG, Pyke SD, Hardy RJ.

Stat Med. 1997 Sep 30;16(18):2063-79.

PMID:
9308132
36.
37.
39.
40.

Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus.

Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA.

Ann Rheum Dis. 1996 Oct;55(10):756-60.

42.

Using a coronary risk score for screening and intervention in general practice. British Family Heart Study.

Thompson SG, Pyke SD, Wood DA.

J Cardiovasc Risk. 1996 Jun;3(3):301-6.

PMID:
8863103
43.

Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study.

Wonderling D, McDermott C, Buxton M, Kinmonth AL, Pyke S, Thompson S, Wood D.

BMJ. 1996 May 18;312(7041):1269-73. Erratum in: BMJ 1996 Jul 27;313(7051):198.

44.
45.

The relationship between CDC light-trap and human-bait catches of endophagic sandflies (Diptera: Psychodidae) in the Peruvian Andes.

Davies CR, Lane RR, Villaseca P, Pyke S, Campos P, Llanos-Cuentas A.

Med Vet Entomol. 1995 Jul;9(3):241-8.

PMID:
7548940
46.

Dietary change after smoking cessation: a prospective study.

Thompson RL, Pyke SD, Scott EA, Thompson SG, Wood DA.

Br J Nutr. 1995 Jul;74(1):27-38.

PMID:
7547826
47.

Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.

Ames PR, Pyke S, Iannaccone L, Brancaccio V.

Thromb Haemost. 1995 May;73(5):768-73.

PMID:
7482401
48.

Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity.

Davies CR, Llanos-Cuentas EA, Pyke SD, Dye C.

Epidemiol Infect. 1995 Apr;114(2):297-318.

50.

Supplemental Content

Support Center